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ABSTRACT
The number of lung cancer cases estimates globally 2 million according to WHO, which represents approximately 
11.6% of all cancers. The problem of lung diseases among women and women’s lung cancer is relatively not often 
discussed in the literature. There is evidence that there is a different distribution of histological types between 
sexes. The prevalence of adenocarcinoma (ADC) among women is observed for many years with an increasing 
tendency. This review focuses on the lung cancer risk factors such as tobacco smoking, second-hand smoke 
exposure, genetic and environmental factors, comorbidities and infectious agents. The declining tendency in 
smoking points to the necessity of focusing on other risk factors. Analysis of them within the context of morbidity 
and mortality can help to develop more effective screening programs. 
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Introduction
The number of lung cases estimates at 2 million ac-
cording to WHO, which represents approximately 11.6% 
of all cancers. Global statistics concerning women show 
725 thousand new cases and 576 thousand deaths due to 
that reason in 2018. The highest female age-standardised 
rate per 100,000 is observed in Hungary, Denmark, 
Netherlands (41.4–32.7) [1, 2]. In Poland, 7747 new cases 
among women were reported in 2017. Unfortunately, 
the number of deaths per year was higher — 7825 [3]. 
The 5-year life expectancy of patients with lung cancer 
is estimated at 13.5% [4]. 
Large analysis relating global patterns and temporal 
trends in incidence and mortality of lung cancer based on 
data from high-quality cancer registries was conducted 
by Wong et al. The conclusions revealed increasing 
trends of incidence among women in 19 countries, one 
with decreasing incidence, and 18 countries with stable 
incidence out of 38 countries. There were 16 coun-
tries with increasing mortality trends, 6 countries with 
decreasing trends and 14 countries with stable trends 
among women out of 36 countries [5]. The ageing of the 
female population born after World War II and their 
high tobacco consumption, improvement of health care 
of chronic diseases can partly explain that appearance. 
There is evidence that there is a different distribu-
tion of histological types between sex. The prevalence 
of adenocarcinoma (ADC) among women is observed 
for many years with an increasing tendency. In one large 
study, the data concerning the epidemiology of ADC are 
presented based on cancer registry (Cancer Incidence in 
Five Countries, CI5) in the years 1998–2002 [6]. An in-
crease of age-adjusted incidence of ADC among women 
was observed in all countries; in some countries, it was as 
high as twofold. The mean proportion of ADC of all lung 
cancer histological subtypes was higher among women 
than among men (45 vs. 34%, respectively). 
The influence of sex is also the subject of study 
in lung cancer treatment. The goal of the Swedish 
nationwide cohort was an analysis of the differences 
in prognosis after pulmonary resection for lung can-
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cer between men and women. The results show that 
women who underwent pulmonary resections for lung 
cancer had a significantly better prognosis than men 
[7]. The progress of new systemic therapies: molecular 
guided and immune-based therapy contributed to the 
improvement of survival in NSCLC. The benefit seems 
to be better among women than in men: 2-years survival 
improved from 26 to 35% in men and from 35 to 44% 
among women in the US from 2001 to 2016 [8].
The problem of lung diseases among women and 
women’s lung cancer is relatively not often discussed 
in the literature and has not been embedded in clini-
cal practice. Current aspects of lung cancer among 
women including the latest topics for research and the 
evidence on the specificity of female lung cancer were 
summarized in the authors’ previous review [9]. This 
review focuses on the risk factors which are special for 
this serious disease among women. Some aspects of 
this problem are well documented, some of them ap-
pear in the minds of researchers. The authors believe 
that this overview will enrich the clinical practice of 
oncologists. 
Tobacco smoking
There is no doubt that smoking remains the main 
factor that causes lung cancer [10]. Tar which is formed 
after removing nicotine and water from cigarette smoke 
consists of about 3500 different compounds and most 
of them are carcinogenic [11]. 
There is a widespread opinion that lung cancer 
incidence is higher among smoking men than women 
and never-smoking women than men. The higher sus-
ceptibility by women to tobacco smoke was postulated. 
Whereas the large epidemiological studies did not 
confirm this view and only a nonsignificant tendency 
supporting it was shown [12, 13]. Even reverse relation-
ships have been found in the large observation in the 
United States population the age-standardized lung 
cancer death rates among never-smoking men was 
17.1/100 000 vs. 14.7/100 000 in women [14]. It should 
be pointed that it concerns one country, and it was race 
dependent. 
Fortunately, the latest global trends estimated by 
WHO points out that the rates of prevalence of current 
tobacco use are declining (Fig. 1). The total number of 
smoking women is predicted to be reduced to 212 mil-
lion by 2025 [15]. This reduction is observed in all world 
regions being slowest in European countries. However, 
cigarette smoke remains a “legally available consumer 
product which kills people”. The increase in the num-
ber of tobacco smoke victims is highest in developing 
countries. Cigarette consumption is still very high 
among women in these countries with the prevalence 
of young women [15]. Recently, two-thirds of smokers 
are citizens of 10 countries, among them: Indonesia, 
Bangladesh, Turkey. 
Unfortunately, Poland is a country with high tobacco 
consumption. Thus, the Polish data is presented. The es-
timated current tobacco smoking prevalence (age-stand-
ardised rate) in Polish females is 21.6% (vs. 30.3% in 
men) and it also shows declining trends over the last 
eleven years [16]. The most recent Polish representa-
tive survey reporting the prevalence of smoking (from 
2019) reveals that the highest prevalence of smoking 
was observed among women aged 30–39 years. It is no-
ticeable that divorced women smoked more often than 
married, single or widowed. Women smoked the most 
in cities between 20,000–500,000 citizens. They choose 
mainly regular cigarettes and hand-rolled tobacco prod-
ucts. Heated tobacco products and smokeless tobacco 
use are not popular in Polish women (2.1% and 0.6%, 
respectively) [17]. 
Considering the influence of e-cigarettes on the lung 
a few toxicological studies were conducted. The results pay 
attention to their adverse effects like cytotoxicity, oxidative 
stress and inflammatory response, reduction of the features 
of obturation in pulmonary function tests (FEV1/FVC) and 
a fraction of exhaled nitric oxide (FENO). The authors 
warn about the lack of studies involving the long-term 
health impact of these products [18]. It should be high-
lighted that the carcinogenic effect of classic cigarettes is 
incomparably higher than these products. 




















































Figure 1. Global trends in the prevalence of tobacco use by 
sex based on World Health Organization [11]
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ETS exposure
Monitoring decreasing global tendency of smok-
ing habit and taking into consideration diagnosis of 
lung cancer in never-smokers (10–15% of all cases) 
[19] one should focus on finding other risks factors of 
lung cancer. The problem, which is much more pre-
dominant among women than in men is second-hand 
smoke exposure (environmental tobacco smoke, ETS). 
In 2004 Oberg and at. conducted analysis of data from 
192 countries which estimates that 35% of non-smoking 
females were exposed to second-hand smoke what had 
resulted in death from ischaemic heart disease, lower 
respiratory infections, asthma, and lung cancer. In total 
603,000 deaths were attributable to second-hand smoke 
and lung cancer was a cause of 21,400 deaths. More 
deaths from second-hand smoke occurred among wom-
en (47%, compared to 26% in men) in this cohort [20]. 
It gives the reason for concerning the necessity of imple-
mentation of careful asking females about second-hand 
smoke exposure in medical anamneses and considering 
the participation of them in screening programs.
Genetic risk factors
Wakelee et al. [12] conducted a review based on 
the large, population-based cohorts which revealed 
that age-adjusted incidence rates of lung cancer 
among never-smokers aged 40 to 79 years ranged from 
14.4 to 20.8 among women and 4.8 to 13.7 in men 
(per 100,000 person-years) what indicate that women 
are more likely than men to have lung cancer without 
smoking history and that genetic factors may be re-
sponsible for this fact. The primary characteristics of 
never-smokers compared to tobacco smokers with lung 
cancer are female sex, ADC histology and East Asian 
ethnicity [21–23]. 
The development of molecular pathology leads to 
precision diagnosis for lung cancer with recognition of 
molecular alterations which are the basis for target-
ed therapies [24]. Epidermal growth factor receptor 
(EGFR) and KRAS activating mutations are the most 
common in ADC. The proportion of molecular alter-
ations incidence depends on smoking history, ethnicity 
and sex [25]. EGFR mutation occurs in the Asian popula-
tion more often than in the Western population (47.9% 
vs. 19.2%) [26], and more often in non-smokers (43% 
vs. 11% in smokers) [27]. EGFR mutation is observed 
among Asian women even up to 60% [28]. In general, 
the most frequently observed mutated gene is p53. The 
prevalence of KRAS mutations is estimated at 15–30% 
[29]. Different genetic alterations are depending on the 
histopathologic type of lung cancer. The most frequently 
mutated genes in ADC are KRAS, EGFR, MLL3, and 
STK11; whereas in squamous cell carcinomas, there 
are PI3KCA, SOX2, CDK2, P63, FGFR1 and in small 
cell lung cancer: RB1, MLL2, SMO, and PI3KCA. An-
ticancer drug development has been made possible by 
anti-EGFR and anti-ALK/ROS1 therapeutics (tyrosine 
kinase inhibitors, TKIs) which play a critical role in the 
treatment of a selected group of patients [30, 31]. The 
greater benefit of TKIs is observed among women than 
in men. 
When investigating the subject of genetic reasons of 
lung cancer, one cannot ignore genome-wide association 
studies that showed that variations at 5p15.33, 6p21.33, 
and 15q25.1, 9p21.3 can influence the risk of cancer in 
European populations [11, 32].
In a study from 2020, Xuemei Ji et al. [33] suggest 
KIAA0930 as a novel candidate gene for lung cancer 
risk (located at 22q13.31). 
Other individual factors 
A systematic review was performed to check if family 
history of lung cancer influences lung cancer risk. The 
results based on twenty-eight publications revealed that 
lung cancer risk of the probands’ first-degree relatives 
was 1.88 times higher than that of their controls [34]. 
However, a family history of lung cancer was not asso-
ciated with the female sex in the EGFR mutated cohort 
in the Gaughan et al. study [35]. 
Recently an interesting report showed two cases of 
paediatric lung cancers that probably developed through 
mother-to-infant transmission of cervical carcinoma. 
The authors assume that tumours arose from moth-
er-to-infant vaginal transmission through aspiration of 
tumour-contaminated vaginal fluids during birth. They 
observed a similarity of the gene profiles of the tumour 
samples from the mothers and children [36].
The role of oestrogens in lung cancer development 
and progression is well established [37, 38] and previ-
ously described by the authors in details [9]. Briefly: 
oestrogen receptors are identified in lung tissue, cancer 
tissue and the cells which form tumour environment 
[39]. Thus, lung cancer development is modified by 
oestrogens from outside as well as produced locally. 
Aromatase (ARO) extensively expressed in NSCLC 
contributes to local oestrogen production. All the above 
data support hormonal influence on lung cancer among 
women with some therapeutic implications [40]. Female 
sex could be a factor considered as that, which influence 
lung carcinogenesis. 
Environmental factors
The harmfulness of the environment also applies 
to lung cancer. An important risk factor for lung can-
cer among women is using solid fuels (coal, biomass, 
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and mixed fuels) for in-home cooking or heating. It is 
noticed mainly in developing countries. A meta-anal-
ysis that included studies from Asia, the USA, South 
America and Europe estimates that the risk of lung 
cancer among users of solid fuels is 70% higher than 
non-users [41].
Air pollution and precisely exposure to particulate 
matter (PM) in outdoor air pollution with aerody-
namic diameter ≤ 2.5 μm or fine particles (PM2.5) and 
particles ≤ 10 μm or inhalable particles (PM10) has an 
association with the risk of lung cancer [42, 43]. World 
Health Organization declares diesel engine exhaust 
as a carcinogen based on evidence of a link with lung 
cancer [44, 45]. What is more, scientists consider gase-
ous pollutants, such as sulphur dioxide (SO2), ozone 
(O3), carbon monoxide (CO), and nitrogen dioxide 
(NO2) as potential risk factor. However, results in that 
topic from previous studies seem to be inconsistent 
[46, 47]. Occupational carcinogens are well known 
for years and, what is interesting, a recently published 
systematic review confirms the increasing role of these 
risk factors [48]. According to the Global Health Data 
Exchange, the following agents relate to the death of 
cancer: arsenic, asbestos, benzene, beryllium, cadmium, 
chromium, diesel engine exhaust, formaldehyde, nickel, 
polycyclic aromatic hydrocarbons, silica, sulfuric acid, 
and trichloroethylene. Most of them relate to lung 
cancer and the risk for death after exposure to oc-
cupational agents increases in both sexes. One of the 
serious carcinogens is naturally occurring radon, which 
is considered as a second lung cancer risk factor after 
smoking. The large analysis of the studies conducted 
in never-smokers confirmed the relationship between 
residual radon and lung cancer, which was higher 
in never than in ever smokers and among man than 
women [49]. However, the synergistic effect of radon 
with smoking was pointed in this review leading to the 
conclusion, that, for both sexes, people living in the 
radon-prone area (> 100 Bq/m3) should be considered 
as a high-risk group. 
Knowing a passion for dieting among women it 
is worth to also approach some information about it. 
In an updated comprehensive literature review based 
on 58 articles, Fakhri et al. summarized information 
about diet and its potential influence on lung cancer. 
A higher risk of lung cancer could be linked to red meat, 
processed meat, and foods high in total or saturated 
fats [50]. Some observations present the protective ef-
fect on lung parenchyma of some items in the diets like 
fruits, vegetables, fish, nuts, soy, B vitamins, vitamin D, 
vitamin E, vitamin C, and zinc. However, US Preventive 
Services Task Force (USPSTF) concluded that there is 
still insufficient evidence to recommend any vitamins, 
minerals, and multivitamin supplementation for lung 
cancer prevention [25, 51]. 
Comorbidities
The well-known factors for lung cancer are also 
chronic pulmonary diseases like chronic obstructive 
pulmonary disease (COPD) and fibrotic lung diseas-
es. The women who reported COPD were 1.64 times 
more likely to develop lung cancer than those who 
reported no history of COPD in a recent analysis, 
after adjusting for smoking status and intensity, eth-
nicity, education, BMI and income. The other results 
show that the associations between COPD and lung 
cancer were similar across subtypes after adjusting for 
smoking status and intensity [52]. Numerous clinical 
problems may occur due to the similarity of the clinical 
picture of lung cancer and COPD and because of that 
sometimes a proper diagnosis and appropriate treat-
ment are implemented with delay [53]. Women seem 
to have a different clinico-radiological phenotype of 
COPD than men [54]. There is evidence that women 
produce less sputum than men despite this, they are 
more likely to have a chronic bronchitic phenotype 
[55]. However, the results of the study conducted by 
Kiri et al. [56] showed that COPD increased 3-year 
mortality in patients with NSCLC regardless of patient 
age or sex (higher mortality rates was observed above 
all in patients aged > 65 years). On the other hand 
in another study, no significant differences in overall 
survival between COPD and non-COPD patients with 
lung cancer have been noticed [57].
The association between lung cancer and interstitial 
lung disease (ILD) can be partly explained by the his-
tory of smoking and physiopathology of fibrogenesis 
and cancerogenesis. The relative risk of lung cancer 
is estimated to be 3.5- to 7.3-times higher in patients 
with ILD and lung cancer is diagnosed among them at 
10–20% [58]. The association between ILD and lung 
cancer among women compering to men need more 
detailed investigation. 
Infectious agents 
The role of inflammation in favouring carcinogenesis 
is well known and the pathomechanisms of immune 
response in lung cancer are widely investigated in the 
last years [24]. However, it is difficult to present the 
differences between sex in these processes. Only the 
results of immunotherapy were found to be better or 
worse among women depending on the study [9]. Thus, 
one aspect of inflammation connected with infections 
is presented. Considering infectious risk factors of lung 
cancer in females one cannot ignore the influence of vi-
ral infections in particular human papillomavirus (HPV) 
and HIV. In various studies, the presence of oncogenic 
HPV DNA (type 16 and 18) in lung tumour tissues was 
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identified [59]. In an international pooled analysis HPV 
was found to be present more likely in lung cancer tissue 
than normal lung [60]. The meta-analysis conducted by 
Zhai K et al. indicated that lung with HPV infection 
has a strong association with lung cancer. Principally, 
HPV 16 and 18 infections significantly increase the risk 
of lung squamous cell carcinoma [61]. This may lead to 
reflect on a special screening for lung cancer in women 
with HPV infection.
Non-AIDS defining cancers (NADC) are an impor-
tant cause of morbidity and mortality in HIV-positive 
individuals. NADCs of the lung are mostly comprised 
of non-small cell lung cancer (NSCLC), followed by 
small cell lung cancer (SCLC). The incidence of lung 
cancer in HIV-infected persons estimates 80–170 cases 
per 100,000 person-years [62, 63]. The hypothesis for 
association between lung cancer and HIV infection 
refers to chronic pulmonary inflammation connected 
with infections contributes to carcinogenesis [64]. The 
role of HIV infection alone was also investigated. The 
results are inconclusive. Sigel et al. [56] indicated that 
HIV was an independent risk factor for lung cancer 
after controlling for potential confounders including 
smoking. On the other hand, Hessol et al. [65] showed 
that HIV infection alone was not an independent risk 
factor for lung cancer but that the amount of cigarette 
smoking and prior AIDS pneumonia were major 
factors for the development of lung cancer among 
HIV-infected patients.
COVID-19 infection involving currently according to 
WHO more than 100 million confirmed cases and caus-
ing more than 2 million death globally is a new factor 
which causes the acute respiratory disorder. There are 
some clinical findings in COVID-19 patients which are 
also reported to be high-risk findings associated with 
lung cancer development. However, the speculations 
about the impact of COVID-19 on lung cancer risk 
seem to be premature
The ground-glass opacity (GGO) (widespread 
among COVID-19 patients) is a frequent radiological 
finding in a patient with lung cancer [66, 67]. The strat-
egy for GGO in lung cancer screening is the subject of 
international discussions and regulations. There may be 
a need for follow up in the patients with persistent GGO 
after SARCov-2 infection for early detection of the 
pre-neoplastic lesions [68]. Another common aspect of 
COVID-19 infection and lung cancer are disturbances in 
the immune system. In the blood of COVID-19 infected 
patients the concentration of IL-6, IFNg, MCP1, and IP-
10 were found to be elevated during COVID-19 [69, 70]. 
These cytokines are involved in invasion, metastasis, 
and epithelial-mesenchymal transition in lung cancer. 
An interesting current result of meta-analysis includ-
ing 3,111,714 globally reported cases of confirmed 
COVID-19 patients showed that there is no difference 
in the proportion of infection between males and fe-
males, however, men have almost three times the odds 
of requiring intensive treatment unit admission and 
higher odds of death compared to women. These results 
have highlighted the importance of considering sex as 
a variable in fundamental and clinical research and can 
help in the clinical management of COVID-19 [71]. The 
new global problem which is COVID-19 needs further 
investigations. 
Conclusion
Lung cancer, which has been associated with the 
male sex for years, has become a serious problem 
among women. The declining tendency in smoking 
induces focusing on other risk factors. An analysis of 
current risk factors within the context of morbidity 
and mortality can help to develop effective screening 
programs. The most important risk factors which need 
intensive investigations for lung cancer in women are 
summarized in Figure 2. 
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Figure 2. Possible and documented risk factors for lung cancer 
among women; ARO — aromatase; ER — oestrogen receptor; 
E2 — 17-b-oestradiol; ETS — environmental tobacco smoke; 
COPD — chronic obstructive lung disease; HPV — human 
papillomavirus; HIV — human immunodeficiency virus; 
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